Crohn's Disease Research Studies

Contact Information
University of Wisconsin GI and Hepatology Clinical Research Office:
(608) 263-4185
Learn more about clinical trials at
Principal Investigator (PI): Mark Reichelderfer, MD
Enrollment Target: 4 patients
Phase IIB double-blind, placebo-controlled, randomized study. Compare certolizumab pegol and placebo treatments in patients who have been successfully withdrawn from prednisone or prednisolone.
  • Moderate to severe Crohn's disease
  • Exclusion: Prior treatment with anti-TNF therapy
Adacolumn 208
Principal Investigator (PI): Sigurdur Einarsson, MD
Enrollment Target: 15 patients
Evaluating an investigational device, Adacolumn Apheresis, in the treatment of Crohn's disease. Purpose is to remove certain white blood cells.
  • Prior Adacolumn Apheresis treatment
  • Moderate to severe Crohn's disease
  • Not currently on Remicade (or used within 8 weeks)
  • Maximum 20 mg prednisone
  • A number of Crohn's disease medications are allowed - however, they have to be stable doses for 2-4 weeks, depending on the medication 
Contact Information

If you are a patient interested in learning more about our clinical studies, or if you are a referring physician and believe one of your patients may be appropriate for one of these trials, please call the University of Wisconsin GI and Hepatology Clinical Research Office at (608) 263-4185.